Get the Stockscreener App
0.298
0.17%
-0.0005
IGC Pharma Inc stock is traded at $0.298, with a volume of 368.91K.
It is down -0.17% in the last 24 hours and up +20.16% over the past month.
India Globalization Capital, Inc. engages in the development and commercialization of cannabis-based therapies to treat Alzheimer's, pain, nausea, eating disorders, several end points of Parkinson's, and epilepsy in humans, dogs, and cats. The company operates through two segments, Legacy Infrastructure and Medical Cannabis Based Alternative Therapies. The Legacy Infrastructure segment trades in infrastructure commodities, such as steel and iron ore; and rents heavy equipment. The Medical Cannabis Based Alternative Therapies segment offers IGC-501 for indications of neuropathic pain; Serosapse for indications of Parkinson's and other central nervous system disorders; Caesafin for seizures in cats and dogs; and Natrinol for indications of cancer and AIDS induced nausea and vomiting, as well as Hyalolex for Alzheimer's patients. The company was founded in 2005 and is based in Bethesda, Maryland.
See More
Previous Close:
$0.2985
Open:
$0.2974
24h Volume:
368.91K
Relative Volume:
0.56
Market Cap:
$30.81M
Revenue:
$1.27M
Net Income/Loss:
$-7.12M
P/E Ratio:
-5.7088
EPS:
-0.0522
Net Cash Flow:
$-5.28M
1W Performance:
-3.87%
1M Performance:
+20.16%
6M Performance:
+2.83%
1Y Performance:
-31.96%
1-Day Range:
$0.2959
$0.30
1-Week Range:
$0.2941
$0.3191
52-Week Range:
$0.235
$0.4549
IGC Pharma Inc Stock (IGC) Company Profile
Name
IGC Pharma Inc
Sector
Industry
Phone
301-983-0998
Address
4336 Montgomery Avenue, Bethesda, MD
Compare IGC vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IGC
IGC Pharma Inc
|
0.298 | 28.66M | 1.27M | -7.12M | -5.28M | -0.0522 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
IGC Pharma Inc Stock (IGC) Latest News
MicroCaps IGC, BIVI, ORBS, RIME Sub-$1 Stocks to Watch Now - openPR.com
IGC Pharma earnings matched, revenue fell short of estimates By Investing.com - Investing.com India
IGC (IGC) Earnings Data Review: The Bottom-Line Figure Outpaces Its Comparison at the Close; Session Reaction: Shares Move 1.43% Higher in the Current UpdatePost-Earnings Reaction - vinanet.vn
IGC Pharma earnings matched, revenue fell short of estimates - Investing.com
IGC Pharma Releases Q2 2026 Financial Results - AlphaStreet
VivoSim Labs (NASDAQ: VIVS) Among IGC, OSRH, IVF as FDA-Backed Human-Based Testing Gains Momentum - openPR.com
IGC Pharma Q2 Results: Sales up 39% YoY, EPS loss widens to $(0.03) - scanx.trade
IGC Looks 24.1% Overvalued on GF Value™ - GuruFocus
IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure - Finviz
IGC Pharma Q2 Results: CALMA Nears Enrollment Closure - accessnewswire.com
IGC Pharma, Inc. 2026: Revenue $265K, EPS ($0.03) — 10-Q Summary - TradingView
IGC Pharma (NYSE: IGC) widens loss while Phase 2 Alzheimer’s trial hits key milestone - Stock Titan
IGC Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Microcaps TOON, IGC, SURG, MDXH to Watch Now as Earnings, AI and Biotech Catalysts Build - openPR.com
IGC Pharma (NYSE American:IGC): What Does the Latest Update Mean for Clinical Development? - Kalkine Media
IGC Pharma Inc (IGC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
IGC Pharma (NYSE AMERICAN:IGC): What Could Today’s regulatory execution Update Reveal? - Kalkine Media
IGC Pharma (NYSE AMERICAN:IGC): What Could Today’s cannabinoid research progress Update Reveal? - Kalkine Media
Early Alert: PLAG, PRSO, UZX, IGC Lead Sub-$1 Stocks to WatchPlus More in Focus - openPR.com
Early Alert: PLAG, PRSO, UZX, IGC Lead Sub-$1 Stocks to Watch – Plus More in Focus - FinancialContent
IGC Looks 21.6% Overvalued on GF Value™ - GuruFocus
IGC Pharma Advances CALMA Toward Q4 Topline Readout - ACCESS Newswire
IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout - Corsicana Daily Sun
IGC Pharma (IGC) Climbs 5% to $0.28, Testing Key Resistance at $0.29Statistical Arbitrage - vinanet.vn
IGC Pharma Inc (IGS1.DU) balance sheet - Yahoo Finance UK
Enterprise value to revenue forward of IGC Pharma, Inc. – AMEX:IGC - TradingView
IGC Pharma Inc (IGC) Stock News Today - TradingKey
Price to sales forward of IGC Pharma, Inc. – MUN:IGS1 - TradingView
Bullish Volume: RITR, IGC, BJDX, CISS Lead Active Sub-$1 Stocks to Watch - openpr.com
IGC Pharma Evaluates Recovery After Left Verdict - ACCESS Newswire
IGC Q1 2026 Earnings: Narrower-Than-Expected Loss Marks 14.16% EPS BeatQuarterly Earnings Report - vinanet.vn
Microcaps MGRX, PRSO, IGC, KUST In the News to Watch - openPR.com
IGC Pharma, Inc. Revenue Breakdown – AMEX:IGC - TradingView
IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign - The Batesville Daily Guard
IGC|IGC Pharma Inc|Price:0.266|Chg%:+0.002 - TradingKey
IGC Pharma Hovers Near Support as Slight Decline Tests $0.26 LevelRetail Volume - vinanet.vn
IGC|IGC Pharma Inc|Price:0.248|Chg%:-0.001 - TradingKey
IGC Pharma Inc (IGC) Cash Flow - TradingKey
IGC Pharma Inc (IGC) Balance Sheet - TradingKey
IGC Pharma Inc (IGC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
IGC Pharma Inc (IGC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
IGC Pharma Inc (IGC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
IGC Pharma, Inc. Revenue Breakdown – SWB:IGS1 - TradingView
IGC Pharma, Inc. Revenue Breakdown – LS:A1T87A - TradingView
IGC Q1 2026 Earnings: Narrowed Loss Beats Expectations Despite Lack of Revenue DisclosureEPS Estimate Trend - Vinanet
IGC Pharma Inc (IGC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
IGC Pharma Inc (IGS1.DU) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Enterprise value to revenue forward of IGC Pharma, Inc. – SWB:IGS1 - TradingView
Price to earnings forward of IGC Pharma, Inc. – SWB:IGS1 - TradingView
IGC Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Market ResponseCFO Commentary Report - vinanet.vn
IGC Q1 2026 Earnings: Loss Narrows on Lower Expenses; Stock Gains 1.44%High Estimate Range - vinanet.vn
IGC Pharma Inc Stock (IGC) Financials Data
Revenue
Net Income
Cash Flow
EPS
IGC Pharma Inc Stock (IGC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mukunda Ram | CEO |
Apr 01 '26 |
Option Exercise |
0.13 |
656,410 |
84,000 |
4,649,088 |
| Mukunda Ram | CEO |
Apr 01 '26 |
Option Exercise |
0.00 |
49,999 |
0 |
910,751 |
| Moran James P | Director |
Apr 01 '26 |
Option Exercise |
0.00 |
130,000 |
0 |
1,235,735 |
| GRIMALDI CLAUDIA | PFO |
Apr 01 '26 |
Option Exercise |
0.15 |
238,462 |
36,000 |
1,372,714 |
| Mukunda Ram | CEO |
Feb 03 '26 |
Option Exercise |
0.00 |
50,000 |
0 |
860,752 |
| PRINS RICHARD K | Director |
Jan 19 '26 |
Option Exercise |
0.00 |
100,000 |
0 |
1,371,251 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):